What we know or can deduce about NOXCOVID:
- Noxopharm must have evidence that Veyonda can stop a cytokine storm. Why would a small company spend millions of dollars on a trial, unless it had reason to believe its drug might be effective?
- Dr Gartier of the Hudson Institute is a leader in STING and Septic Shock research. Dr Gartier discovered that Veyonda inhibits STING when it is acting abnormally, which then inhibits a wide range of cytokines associated with death and disability in COVID-19 patients
- Inhibition of IL-6 alone does not work. Sanofi recently announced that IL-6 inhibitor Kevzara failed its Phase III trial against severely or critically-ill COVID 19 patients. See https://tinyurl.com/y3kdl7b5
- The primary endpoint was time to improvement of 2 points or greater on a 7-point clinical scale (where 1=death; 2=hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation;3=hospitalized, on non-invasive ventilation or high flow oxygen devices; 4=hospitalized, requiring supplemental oxygen; 5=hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6=hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7=not hospitalized). The key secondary endpoint was percentage of patients alive at Day 29.
- NOXCOVID seeks to help patients before they suffer lethal organ damage. Sanofi appears to have recruited category 2 patients – hospitalized, on invasive mechanical ventilation; whereas Noxopharm looks like it will recruit category 4 patients – hospitalized, requiring supplementary oxygen. The object is to stop the cytokine storm before mechanical ventilation is required.
- Efficacy should be known in a relatively short period. Treatment lasts 14 days, with an option to extend to 28 days. It will not take treating physicians long to know whether patients have regressed to category 3 (need high-flow oxygen); or improved to category 5 (not requiring oxygen).
- Trial Implications. If treatment is effective, the world will be a safer place. The big payoff to Noxopharm, however, is that Veyonda should become the approved drug for Septic Shock – an ongoing problem that kills about 10 million people each year.
- Forums
- ASX - By Stock
- NOXCOVID
What we know or can deduce about NOXCOVID: Noxopharm must have...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.8¢ |
Change
0.006(7.32%) |
Mkt cap ! $25.71M |
Open | High | Low | Value | Volume |
8.4¢ | 8.8¢ | 8.3¢ | $14.98K | 173.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 8.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.8¢ | 6808 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.086 |
2 | 27380 | 0.084 |
2 | 70186 | 0.083 |
3 | 141400 | 0.082 |
1 | 100000 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.088 | 6808 | 1 |
0.091 | 10989 | 1 |
0.092 | 20000 | 1 |
0.094 | 37410 | 1 |
0.095 | 54200 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |